- Home
- KLRS vs CPSH Comparison
KLRS vs CPSH Comparison
Compare KLRS & CPSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- CPSH
- Stock Information
- Founded
- KLRS 2019
- CPSH 1984
- Country
- KLRS United States
- CPSH United States
- Employees
- KLRS N/A
- CPSH N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- CPSH Building Materials
- Sector
- KLRS Health Care
- CPSH Consumer Discretionary
- Exchange
- KLRS Nasdaq
- CPSH Nasdaq
- Market Cap
- KLRS 46.0M
- CPSH 48.2M
- IPO Year
- KLRS N/A
- CPSH 1987
- Fundamental
- Price
- KLRS $3.71
- CPSH $3.39
- Analyst Decision
- KLRS Strong Buy
- CPSH
- Analyst Count
- KLRS 2
- CPSH 0
- Target Price
- KLRS $23.00
- CPSH N/A
- AVG Volume (30 Days)
- KLRS 689.3K
- CPSH 95.6K
- Earning Date
- KLRS 11-15-2025
- CPSH 10-29-2025
- Dividend Yield
- KLRS N/A
- CPSH N/A
- EPS Growth
- KLRS N/A
- CPSH N/A
- EPS
- KLRS N/A
- CPSH N/A
- Revenue
- KLRS N/A
- CPSH $25,764,977.00
- Revenue This Year
- KLRS N/A
- CPSH N/A
- Revenue Next Year
- KLRS N/A
- CPSH N/A
- P/E Ratio
- KLRS N/A
- CPSH N/A
- Revenue Growth
- KLRS N/A
- CPSH 7.46
- 52 Week Low
- KLRS $2.14
- CPSH $1.32
- 52 Week High
- KLRS $24.15
- CPSH $3.72
- Technical
- Relative Strength Index (RSI)
- KLRS 52.79
- CPSH 53.92
- Support Level
- KLRS $2.37
- CPSH $3.31
- Resistance Level
- KLRS $4.90
- CPSH $3.63
- Average True Range (ATR)
- KLRS 0.70
- CPSH 0.24
- MACD
- KLRS -0.02
- CPSH -0.02
- Stochastic Oscillator
- KLRS 24.95
- CPSH 40.00
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About CPSH CPS Technologies Corp.
CPS Technologies Corp provides material solutions to the transportation, automotive, energy, computing/Internet, telecommunications, aerospace, defense, and oil and gas end markets. Its primary material solution is metal matrix composites (MMCs), which are a class of materials consisting of a combination of metal and ceramic. The company designs, manufactures and sells custom MMC components, which manages the performance and reliability of systems in the end markets. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers.